Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 032
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Nov 2019 Data from this trial was used to evaluate the cost-effectiveness of nivolumab versus routine care in 3L SCLC were 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 06 Nov 2019 Results of cost-effective analysis of nivolumab monotherapy versus third-line treatment, presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 17 Oct 2019 Updated results including long-term overall survival (OS), from the randomized cohort published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top